I am a
Home I AM A Search Login

Papers of the Week

Papers: 29 Jul 2023 - 4 Aug 2023

2023 Jul 31

Br J Dermatol


Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: Results from a phase III, randomised, double-blind, placebo-controlled, multicentre study.


Igarashi A, Katsunuma T, Matsumura T, Komazaki H


Atopic dermatitis (AD) is a chronic, inflammatory skin condition affecting up to one-quarter of children. Uncontrolled pruritus associated with childhood AD, and the accompanying scratching, negatively impacts quality of life (QoL), sleep, and development. The humanised monoclonal antibody nemolizumab, used concomitantly with topical agents, was shown to reduce pruritus and improve QoL in patients with AD aged ≥13 years. However, data relating to its efficacy and safety in younger children (aged <13 years) have been lacking.